Johnson & Johnson is partnering with Insuline Medical to register and distribute the Israeli company's InsuPad for promoting optimal absorption of insulin in diabetics by warming their injection site.
Pfizer is walking away from a $70 million collaboration with Waltham, MA's Repligen, handing back some early-stage treatments for the rare spinal muscular atrophy.
Astellas Pharma is teaming up with biotech Immunomic Therapeutics on a vaccine that could relieve a common allergy that affects millions in its native Japan.
Merck KGaA, in the process of paring down its pipeline, is walking away from a $625 million deal with Symphogen and handing back the company's lead asset, a targeted cancer treatment in midstage trials.
In a broad-ranging slate of tech collaborations, AstraZeneca is allying itself with several top research institutions to hone its ability to apply CRISPR gene editing techniques to its drug development work. And the pharma giant used this alliance to pick some of the best brains in the business, without turning to any of the pioneers who have recently spawned a lineup of upstart biotechs.
Australia's PhytoTech Medical last week became the country's first medical marijuana company to first be listed on the country's Australian Securities Exchange, where it raised AUS $5.9 million ($4.7 million) in support of its single-use vaporizer to administer medical marijuana at a precise dosage.
In a win for the Clinton Foundation's goal of preventing 10,000 prescription drug-related deaths over 5 years, privately held kaléo agreed to sell its Evzio Auto-Injector to universities and other institutional buyers at the low federal price.
Sequenom is teaming up with Cypher Genomics to develop a noninvasive prenatal test using the company's advanced genome interpretation screening technology, eyeing a bigger share of an increasingly competitive market.
French in vitro diagnostics outfit bioMérieux and Astute Medical are teaming up to develop Astute's test for acute kidney injury, continuing the companies' recent diagnostics winning streak and helping them capitalize on a growing market.
Kite Pharma, contending with a slew of rivals in the newfangled field of immuno-oncology, has aligned itself with a pioneer in the field, teaming up with an Israeli university to work on treatments that train the body's own defenses on cancerous growth.